New approaches to molecular cancer therapeutics
Ian Collins(Institute of Cancer Research), Paul Workman(Institute of Cancer Research)
Cited by 387
Related Papers
Guidelines for the welfare and use of animals in cancer research
|British Journal of Cancer|2010|1.4k
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
|Molecular Oncology|2012|581
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations
|British Journal of Cancer|2005|513
The Cyclin-dependent Kinase Inhibitor CYC202 (<b><i>R</i></b>-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway
|Cancer Research|2004|194
Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
|Current Medicinal Chemistry|2011|103